registrarjournal.comCellect Announces a Major Milestone for Enabling Stem Cells ProductionPR Newswire (press release)TEL AVIV, Israel, April 9, 2018 /PRNewswire/ — Cellect Biotechnology Ltd. (Nasdaq: APOP), a developer of a novel stem cell enabling te… Continue reading
registrarjournal.comCellect Announces a Major Milestone for Enabling Stem Cells ProductionPR Newswire (press release)TEL AVIV, Israel, April 9, 2018 /PRNewswire/ — Cellect Biotechnology Ltd. (Nasdaq: APOP), a developer of a novel stem cell enabling te… Continue reading
Pharmaceutical Executive |
China’s CAR–T Therapy Race
Pharmaceutical Executive (press release) (blog) On March 12, 2018 the Chinese FDA (CFDA) approved the clinical trial application of LCAR-B38M CAR–T cell self-reinfusion preparation from Nanjing Legend Biotech, marking the first cellular therapy to officially enter the clinical trial stage in China … Dendritic Cell and CAR–T Therapies Market Trends and Segments 2017 – 2025Facts of Week |
Fortune |
Why Novartis Is Paying $8.7 Billion for a Gene Therapy Developer You’ve Never Heard Of
Fortune On Monday, Novartis CEO Vasant Narasimhan announced the company would buy the Illinois-based gene–therapy developer AveXis for $8.7 billion. The acquisition comes only a few months into Narasimhan’s tenure as CEO. AveXis’s main drug treats spinal … Novartis enters deal to acquire gene therapy company AveXis for $8.7 billionCNBC Novartis Bets $8.7 Billion on Gene–Therapy CompanyWall Street Journal Novartis buying gene therapy company AveXis for $8.7 billionUSA TODAY Forbes –STAT –Reuters –Novartis all 110 news articles » |